Background Recombinant proteins and in particular single domains or peptides are often
poorly immunogenic unless conjugated to a carrier protein. Virus-like-particles are a very …

Abstract Virus-like particles (VLPs), aggregates of capsid proteins devoid of viral genetic
material, show great promise in the fields of vaccine development and gene therapy. These …

We have previously demonstrated the formation and release of influenza virus-like particles
(VLPs) from the surface of Sf9 cells infected with either a quadruple baculovirus recombinant …

Highlights•Recent advances in bionanotechnology are poised to have a major impact on
vaccines.•Synthetic particulate vaccines offer advantages for precisely engineered …

Studies on a platform technology able to deliver low-cost viral capsomeres and virus-like
particles are described. The technology involves expression of the VP1 structural protein …

Virus-like particles (VLPs) have been produced as candidate vaccines in plants virtually
since the introduction of biofarming. Even today, VLPs remain the best candidates for safe …

Background The 2009 influenza pandemic and shortages in vaccine supplies worldwide
underscore the need for new approaches to develop more effective vaccines …

Background Influenza A viruses are major human and animal pathogens with huge
economic and societal impact from illness, hospitalizations, and deaths. Virus-like particles …

The simultaneous expression of structural proteins of virus can produce virus-like particles
(VLPs) by a self-assembly process in a viral life cycle even in the absence of genomic …

Vaccination is a key component of public health policy with demonstrated cost-effective
benefits in protecting both human and animal populations. Vaccines can be manufactured …